US 11613739
Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells
granted A61KA61K35/76A61K38/00
Quick answer
US patent 11613739 (Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells) held by REGENXBIO INC. expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENXBIO INC.
- Grant date
- Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K35/76, A61K38/00, A61K47/26, A61K48/00